Reuters logo
BRIEF-Tetra Bio-Pharma, Intelgenx sign ageement to develop and commercialize a dronabinol XL tablet
February 9, 2017 / 1:52 PM / 9 months ago

BRIEF-Tetra Bio-Pharma, Intelgenx sign ageement to develop and commercialize a dronabinol XL tablet

Feb 9 (Reuters) - Intelgenx Technologies Corp

* Tetra Bio-Pharma and Intelgenx announce the signing of a term sheet for the development and commercialization of a dronabinol XL tablet

* Tetra Bio-Pharma - Intelgenx will be responsible for research and development of product, including clinical studies and will develop product as an oral mucoadhesive tablet

* Tetra Bio-Pharma - Tetra will make a non-refundable exclusive negotiation payment to Intelgenx, an upfront payment along with set milestone payments Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below